Akèy › Kansè ovè › North Carolina › Charlotte
Etid klinik pou Kansè ovè nan Charlotte, NC
12 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Charlotte (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Ap rekriteFaz 1
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville · 13 mi lwen
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- Atrium Health Levine Cancer Institute /ID# 274557, Charlotte
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 3
- Levine Cancer Center, Charlotte
- Novant Presbyterian Hospital, Charlotte
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Charlotte
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Ap rekriteFaz 3
- Levine Cancer Institute, Charlotte
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Ap rekriteFaz 1
- Atrium Health - Wake Forest, Charlotte
A Study of DM002 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Carolina BioOncology Institute, LLC, Huntersville · 13 mi lwen
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Clinical Trial Site, Huntersville · 13 mi lwen
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Ap rekriteFaz 2
- GSK Investigational Site, Charlotte
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Carolina BioOncology Institute, Huntersville · 13 mi lwen
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Levine Cancer Institute (LCI)- Atrium Health, Charlotte
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Huntersville · 13 mi lwen
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan Charlotte
- Kansè (tout kalite)27 etid
- Kansè nan tete22 etid
- Myelom Miltip21 etid
- Kansè Poumon ki pa ti selil19 etid
- Leksemi mieloïd egi16 etid
- Obèsite16 etid
- Sipwa15 etid
- Kansè kolorektal13 etid
- Ensifizyans kadyak11 etid
- Kansè Metastatik11 etid
- Karsinòm selil skuamèz tèt ak kou10 etid
- BPCO9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.